Trevi Therapeutics (NASDAQ:TRVI – Get Rating) had its target price lowered by investment analysts at Oppenheimer to $9.00 in a research note issued on Thursday, Stock Target Advisor reports. Oppenheimer's price objective suggests a potential upside of 320.56% from the stock's current price. Oppenheimer also issued estimates for Trevi Therapeutics' Q4 2022 earnings at ($0.09) EPS, FY2022 earnings at ($0.51) EPS, Q1 2023 earnings at ($0.09) EPS, Q2 2023 earnings at ($0.10) EPS, Q3 2023 earnings at ($0.10) EPS, Q4 2023 earnings at ($0.11) EPS, FY2023 earnings at ($0.41) EPS, FY2024 earnings at ($0.44) EPS, FY2025 earnings at ($0.39) EPS and FY2026 earnings at ($0.35) EPS.
Separately, Needham & Company LLC cut their target price on shares of Trevi Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, November 11th.
Get Trevi Therapeutics alerts:Trevi Therapeutics Stock Performance
Shares of NASDAQ:TRVI opened at $2.14 on Thursday. The firm has a market cap of $94.31 million, a PE ratio of -2.74 and a beta of 0.75. The firm's 50 day simple moving average is $2.06 and its 200-day simple moving average is $2.65. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.18 and a current ratio of 8.70. Trevi Therapeutics has a one year low of $0.46 and a one year high of $4.68.
Trevi Therapeutics (NASDAQ:TRVI – Get Rating) last posted its quarterly earnings data on Thursday, November 10th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.03. As a group, equities analysts predict that Trevi Therapeutics will post -0.55 EPS for the current year.Institutional Trading of Trevi Therapeutics
A number of large investors have recently bought and sold shares of the business. Fairmount Funds Management LLC lifted its stake in shares of Trevi Therapeutics by 250.7% in the 3rd quarter. Fairmount Funds Management LLC now owns 5,696,515 shares of the company's stock worth $8,773,000 after acquiring an additional 4,072,126 shares during the period. Rubric Capital Management LP grew its holdings in shares of Trevi Therapeutics by 219.6% during the third quarter. Rubric Capital Management LP now owns 5,684,420 shares of the company's stock worth $8,754,000 after buying an additional 3,906,000 shares in the last quarter. MAI Capital Management purchased a new stake in shares of Trevi Therapeutics during the first quarter worth about $3,391,000. Frazier Life Sciences Management L.P. purchased a new stake in shares of Trevi Therapeutics during the second quarter worth about $3,292,000. Finally, Vanguard Group Inc. boosted its position in shares of Trevi Therapeutics by 459.0% in the third quarter. Vanguard Group Inc. now owns 1,324,377 shares of the company's stock worth $2,040,000 after acquiring an additional 1,087,437 shares during the last quarter.
Trevi Therapeutics Company Profile
(Get Rating)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.
See Also
- Get a free copy of the StockNews.com research report on Trevi Therapeutics (TRVI)
- MarketBeat: Week in Review 11/14 – 11/18
- Target's Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML's November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.